JOURNAL OF PHARMA INSIGHTS AND RESEARCH ISSN NO. 3048-5428

REVIEW ARTICLE

Genetic and Environmental Determinants of Hypertension in African Populations

Oyebamiji Abdulhalim Ololade

PG Scholar, Department of Physiology, College of Health Sciences, University of Ilorin, Kwara State, Nigeria

Publication history: Received on 8th April 2025; Revised on 4th May 2025; Accepted on 5th May 2025

Article DOI: 10.69613/y0nhx821

Abstract: Hypertension is a significant health burden in African populations, characterized by higher prevalence, earlier onset, and more severe complications compared to other ethnic groups. The distinct pathophysiology of hypertension in African populations stems from unique genetic variations, particularly in the renin-angiotensin-aldosterone system (RAAS), endothelial function regulators, and sodium handling genes. These genetic factors interact with environmental influences, including dietary patterns, physical activity levels, and socioeconomic conditions, contributing to the disproportionate impact of hypertension in African communities. Salt sensitivity, a prevalent characteristic in African populations, results from specific genetic polymorphisms affecting renal sodium handling and appears to be exacerbated by modern dietary practices. Recent advances in pharmacogenetics have revealed population-specific responses to antihypertensive medications, suggesting the need for tailored therapeutic approaches. The emerging role of the gut microbiome in blood pressure regulation adds another layer of complexity to the pathophysiology of hypertension in African populations. Combination use of genetic screening, personalized medicine approaches, and culturally appropriate lifestyle interventions may optimize hypertension management in African communities. Additionally, addressing socioeconomic barriers to healthcare access remains crucial for improving outcomes. The next big things in this area include large-scale genetic studies focusing on African-specific hypertension phenotypes, investigation of epigenetic modifications, and development of targeted therapeutic strategies based on individual genetic profiles.

Keywords: Hypertension; African populations; Genetic polymorphisms; Environmental factors; Personalized medicine.

1. Introduction

Hypertension represents a paramount global health challenge, affecting millions worldwide and serving as a primary risk factor for cardiovascular diseases, renal dysfunction, stroke, and transient ischemic attacks [1]. In African populations, hypertension exhibits distinctive epidemiological characteristics, manifesting with greater prevalence, earlier onset, and more severe complications compared to other ethnic groups [2]. The multifactorial etiology underlying these disparities encompasses intricate interactions between genetic predisposition, environmental influences, and socioeconomic determinants [3]. The physiological regulation of blood pressure involves complex mechanisms, with the renin-angiotensin-aldosterone system (RAAS) playing a central role. When homeostatic disruptions occur, the RAAS pathway becomes activated, leading to increased vascular resistance and enhanced sodium and water retention [4]. Genetic variants affecting RAAS components and salt sensitivity, which occur more frequently in African compared to European populations, may explain the heightened susceptibility to hypertension observed in specific ethnic subgroups [5].

Beyond genetic vulnerability, environmental and lifestyle factors significantly influence hypertension susceptibility in African populations. Modern dietary patterns, characterized by increased consumption of processed foods and excessive sodium intake, combined with insufficient potassium consumption, contribute to blood pressure elevation [6]. These factors, coupled with environmental and socioeconomic disparities, affect access to healthcare resources and preventive measures [7].

The interaction between genetic and environmental influences poses significant challenges in managing and preventing hypertension among African populations [8]. Recent advances in genetic research have identified specific polymorphisms associated with hypertension risk and treatment response in African individuals [9]. Additionally, emerging evidence suggests that epigenetic modifications and alterations in the gut microbiome may contribute to hypertension development and progression [10]. This review discusses about the pathophysiological mechanisms for hypertension in African populations, focusing on the relationships between genetic predisposition and environmental factors [11]. The public health initiatives, and personalized treatment methods are discussed, focusing the importance of recognizing population-specific challenges in developing targeted interventions [12].

* Corresponding author: Oyebamiji Abdulhalim Ololade

2. Pathophysiology of Hypertension

2.1. Blood Pressure Regulation

Blood pressure regulation involves intricate physiological mechanisms requiring precise coordination between cardiac output, systemic vascular resistance, renal function, and neurohormonal activity [13]. Disruptions in these regulatory networks lead to sustained hypertension and subsequent cardiovascular complications. The maintenance of normal blood pressure depends on the integration of multiple systems, including the autonomic nervous system, endocrine factors, and local tissue regulators [14].



2.2. Renin-Angiotensin-Aldosterone System (RAAS)

The RAAS plays a pivotal role in long-term blood pressure regulation through its effects on sodium homeostasis, plasma volume, and vascular tone [15]. In response to decreased renal perfusion, renin release initiates a cascade leading to the production of angiotensin I. Subsequently, angiotensin-converting enzyme (ACE) transforms angiotensin I into angiotensin II, a potent vasoconstrictor that stimulates aldosterone release [16].

African populations exhibit distinct variations in RAAS activity, attributed to genetic polymorphisms in key components such as the angiotensinogen (AGT) and ACE genes [17]. These genetic variations may result in enhanced RAAS activity, contributing to the increased prevalence of hypertension observed in African communities [18].

2.3. Vascular Function and Endothelial Regulation

The endothelium serves as a crucial regulator of vascular tone through the production of vasoactive substances, particularly nitric oxide (NO) [19]. Endothelial dysfunction, characterized by reduced NO bioavailability, promotes vasoconstriction and vascular inflammation. Studies indicate that African populations may possess distinct endothelial responses due to genetic determinants affecting vascular reactivity and NO synthesis [20].

Oxidative stress and inflammation further compromise endothelial function, creating a self-perpetuating cycle that maintains elevated blood pressure [21]. The interaction between genetic predisposition and environmental factors, such as dietary habits and physical activity levels, influences the severity of endothelial dysfunction in African individuals [22].

2.4. Sodium Handling and Fluid Balance

Sodium retention represents a fundamental mechanism in hypertension development, particularly in salt-sensitive individuals [23]. Salt sensitivity, more prevalent among African ethnic groups, may reflect genetic adaptations to ancestral environments characterized by low sodium availability [24].

Impaired renal sodium excretion, influenced by polymorphisms in sodium-handling genes such as CYP11B2 and SCNN1A, contributes to blood pressure elevation in African populations [25]. The interaction between these genetic factors and modern dietary practices, often high in sodium content, exacerbates the risk of hypertension development [26].

2.5. Sympathetic Activity

The sympathetic nervous system contributes to blood pressure regulation through its effects on heart rate, cardiac contractility, and vascular tone [27]. Studies suggest that African populations may exhibit enhanced sympathetic nervous system activity, potentially due to genetic variations affecting neurotransmitter metabolism and receptor function [28].

3. Genetic Factors

3.1. Heritability and Population Genetics

Genetic factors significantly influence blood pressure regulation, with heritability estimates ranging from 30-50% in various populations [29]. Family studies demonstrate increased hypertension risk among individuals with hypertensive parents, indicating strong genetic determinants [30]. African populations possess unique genetic adaptations that historically promoted sodium and water conservation, conferring survival advantages in salt-scarce environments. However, these genetic traits may predispose to hypertension in modern settings characterized by high sodium availability [31].

Table 1. Genetic Pathways Linked with Hypertension Among African Populations

Pathway	Physiological Role	Clinical Relevance	Research Status
RAAS Pathway	Blood pressure regulation, fluid balance	Primary therapeutic target	Well-established
Ion Transport	Sodium and potassium homeostasis	Salt sensitivity	Actively studied
Sympathetic Signaling	Vascular tone, heart rate	Treatment response	Emerging evidence
Oxidative Stress	Endothelial function	Target for intervention	Under investigation
Inflammatory Mediators	Vascular remodeling	Novel therapeutic approach	Early research phase

3.2. Genetic Variants Associated with Hypertension

3.2.1. Angiotensinogen Gene (AGT)

The AGT gene, encoding the precursor molecule of angiotensin II, exhibits significant polymorphisms in African populations [32]. Specific variants, particularly the M235T polymorphism, correlate with increased plasma angiotensinogen levels and elevated blood pressure [33]. These genetic variations affect the baseline activity of the renin-angiotensin system, influencing blood pressure regulation and response to antihypertensive medications [34].

3.2.2. Angiotensin-Converting Enzyme Gene (ACE)

ACE gene polymorphisms significantly impact cardiovascular function and blood pressure control in African populations [35]. The insertion/deletion (I/D) polymorphism affects ACE activity levels, with the D allele associated with higher enzyme activity and increased risk of hypertension [36]. These genetic variations influence the effectiveness of ACE inhibitors in blood pressure management [37].

3.2.3. Aldosterone Synthase Gene (CYP11B2)

Variations in the CYP11B2 gene affect aldosterone production and sodium handling [38]. The -344T/C polymorphism, particularly prevalent in African populations, influences aldosterone synthesis and salt sensitivity [39]. These genetic variations contribute to the differential responses observed in blood pressure regulation and antihypertensive therapy [40].

Table 2. Major Genetic Variants Associated with Hypertension in African Populations

Gene	Variant	Population	Functional Impact	Clinical Significance
AGT	M235T	West African	Increased plasma angiotensinogen	Enhanced BP response to salt
ACE	I/D polymorphism	Pan-African	Altered ACE activity	Reduced ACE-inhibitor response
CYP11B2	-344T/C	South African	Modified aldosterone synthesis	Increased salt sensitivity
SCNN1B	R563Q	Southern African	Enhanced sodium channel activity	Salt-sensitive hypertension
GRK4	A142V	African American	Altered D1 receptor function	Impaired sodium excretion
SLC24A5	rs2555364	East African	Calcium homeostasis	Altered vascular reactivity

3.3. Population-Specific Genetic Markers

African populations show complex genetic architectures that substantially influence hypertension susceptibility, progression, and therapeutic outcomes [41]. Contemporary genome-wide association studies, incorporating advanced sequencing technologies and large-scale population databases, have revealed multiple novel loci and genetic variants that exhibit strong associations with blood pressure regulation specifically in individuals of African ancestry [42]. These genetic determinants operate through intricate physiological pathways, often showing population-specific effect sizes and interaction patterns that warrant careful consideration in both research and clinical settings

3.3.1. Sodium Channel Genes

Polymorphisms in epithelial sodium channel genes (ENaC) demonstrate particularly strong effects on renal sodium homeostasis and blood pressure regulation [43]. These genetic variations, which show significantly higher frequencies in populations of African descent, create a physiological predisposition toward enhanced sodium reabsorption and volume expansion [44]. The evolutionary advantage of efficient sodium retention, likely beneficial in historical environmental contexts, now contributes to increased hypertension susceptibility in modern settings where sodium is abundant.

3.3.2. Endothelial Function Genes

Polymorphisms affecting endothelial nitric oxide synthase (eNOS) and related vasoactive mediators create distinct patterns of vascular reactivity and endothelial function [45]. These genetic variations manifest through altered nitric oxide bioavailability, modified endothelial-dependent vasodilation, and unique patterns of vascular remodeling. Such genetic determinants contribute substantially to the distinct cardiovascular phenotypes and blood pressure responses observed in African populations, particularly under conditions of physiological stress or environmental challenges [46].

3.4. Pharmacogenetic Factors

The genetic diversity within African populations significantly affects the individual responses to antihypertensive medications, creating both challenges and opportunities for therapeutic optimization [47]. Understanding these genetic determinants has become crucial for developing precision medicine approaches that account for population-specific variation while acknowledging individual genetic profiles.

3.4.1. Drug Metabolism

The pharmacokinetic and pharmacodynamic profiles of antihypertensive medications are substantially influenced by genetic polymorphisms in drug-metabolizing enzymes, particularly within African populations [48]. These genetic variations affect drug bioavailability, metabolism rates, and therapeutic efficacy, necessitating carefully considered population-specific dosing strategies and drug selection protocols [49].

3.4.2. Treatment Response Prediction

Advanced genetic profiling techniques have enabled the identification of specific genetic markers that serve as predictors of individual responses to various antihypertensive drug classes [50]. This genetic information has profound implications for therapeutic decision-making, allowing for more precise and personalized treatment approaches. The development of targeted therapeutic strategies for African populations, informed by genetic data, represents a significant advance in hypertension management, potentially improving treatment outcomes while reducing adverse effects [51].

4. Environmental and Lifestyle Factors

4.1. Dietary Patterns and Nutritional Factors

4.1.1. Sodium Consumption

Modern dietary practices in African populations have shifted dramatically from traditional eating patterns, with increased sodium intake representing a significant concern [52]. Processed foods, commonly consumed in urbanized areas, contain high sodium levels that exceed physiological requirements [53]. The interaction between elevated sodium intake and genetic predisposition to salt sensitivity amplifies hypertension risk in African populations [54].

4.1.2. Potassium and Mineral Balance

Traditional African diets, rich in potassium and other beneficial minerals, have been largely replaced by processed alternatives [55]. The resulting mineral imbalance, particularly the altered sodium-to-potassium ratio, negatively impacts blood pressure regulation [56]. Studies indicate that insufficient potassium intake correlates with increased hypertension prevalence in African communities [57].

4.1.3. Dietary Fat and Processed Foods

The adoption of Western dietary patterns has led to increased consumption of saturated fats and refined carbohydrates [58]. These dietary changes contribute to obesity, inflammation, and metabolic dysfunction, all of which exacerbate hypertension risk [59]. The synergistic effects of poor dietary choices and genetic susceptibility accelerate cardiovascular disease development [60].

4.2. Physical Activity and Urbanization

4.2.1. Sedentary Lifestyle Patterns

Urbanization has fundamentally altered physical activity patterns in African populations [61]. Decreased occupational physical activity, increased reliance on motorized transportation, and extended periods of sedentary behavior characterize modern lifestyle patterns [62]. These changes significantly impact cardiovascular health and blood pressure regulation [63].

4.2.2. Built Environment

Urban development patterns often create environments that discourage physical activity [64]. Limited access to safe recreational spaces, poor walkability, and inadequate infrastructure for active transportation contribute to reduced physical activity levels [65]. These environmental barriers disproportionately affect lower-income communities [66].

4.3. Socioeconomic Determinants

4.3.1. Access to Healthcare

Socioeconomic disparities significantly influence hypertension management in African populations [67]. Limited access to healthcare facilities, inadequate medical resources, and financial constraints impede proper diagnosis and treatment [68]. These barriers contribute to poor blood pressure control and increased complications [69].

4.3.2. Health Literacy and Education

Educational disparities affect understanding of hypertension risk factors and management strategies [70]. Limited health literacy impacts medication adherence, lifestyle modifications, and preventive care [71]. Cultural beliefs and traditional practices may also influence healthcare-seeking behaviors [72].

4.3.3. Economic Stress

Financial hardship creates chronic stress that directly impacts blood pressure regulation [73]. Limited economic resources affect access to healthy foods, medical care, and preventive services [74]. The cumulative impact of economic stress contributes to higher hypertension prevalence in disadvantaged communities [75].

5. Interaction Between Genetic and Environmental Factors

5.1. Gene-Environment Relationship

5.1.1. Molecular Mechanisms

The expression of genetic predispositions to hypertension depends significantly on environmental triggers [76]. Epigenetic modifications, induced by environmental factors, alter gene expression patterns without changing DNA sequences [77]. These modifications affect multiple physiological systems involved in blood pressure regulation, including RAAS components and vascular function mediators [78].

5.1.2. Dietary Influences on Gene Expression

Dietary factors modulate the expression of genes involved in blood pressure regulation [79]. High sodium intake particularly affects the expression of sodium-handling genes, with more pronounced effects in individuals carrying specific genetic variants [80]. The interaction between dietary patterns and genetic polymorphisms explains part of the variation in hypertension susceptibility among African populations [81].

5.2. Stress-Related Mechanisms

5.2.1. Physiological Stress Response

Chronic stress activates neuroendocrine pathways that influence blood pressure regulation [82]. Genetic variations in stress response genes modify individual susceptibility to stress-induced hypertension [83]. African populations may exhibit unique stress response patterns due to specific genetic variants affecting sympathetic nervous system activity [84].

5.2.2. Oxidative Stress

Environmental factors, including diet and pollution, generate oxidative stress that impacts vascular function [85]. Genetic variations in antioxidant enzymes and stress response proteins influence individual susceptibility to oxidative damage [86]. The combination of environmental oxidative stress and genetic predisposition accelerates vascular aging and hypertension development [87].

5.3. Developmental Programming

5.3.1. Early Life Influences

Environmental exposures during critical developmental periods can permanently alter blood pressure regulation [88]. Maternal nutrition, stress, and environmental toxins influence fetal programming of cardiovascular function [89]. These early life influences interact with genetic factors to determine lifetime hypertension risk [90].

5.3.2. Transgenerational Effects

Environmental influences may induce epigenetic modifications that persist across generations [91]. These inherited epigenetic changes affect blood pressure regulation in subsequent generations [92]. Understanding transgenerational effects is important for developing preventive measures [93].

5.4. Microbiome Interactions

5.4.1. Gut Microbiota Composition

Diet and environmental factors shape gut microbiota composition, which influences blood pressure regulation [94]. Genetic variations affect host-microbiome interactions and metabolic processes [95]. The gut microbiome represents a crucial interface between genetic and environmental factors in hypertension development [96].

5.4.2. Metabolic Pathways

Microbial metabolites influence various physiological processes involved in blood pressure regulation [97]. Genetic variations affect the processing and response to these metabolites [98]. The interaction between host genetics and microbiome-derived compounds contributes to individual variation in hypertension susceptibility [99].

6. Diagnosis and Treatment

6.1. Personalized Medicine

6.1.1. Genetic Profiling

The integration of genetic information into clinical decision-making represents a paradigm shift in hypertension management, particularly relevant for African populations with their distinct genetic architectures [100]. This method transcends traditional treatment algorithms by incorporating individual genetic variations that influence both disease susceptibility and therapeutic outcomes. Advanced genetic profiling enables clinicians to identify specific polymorphisms affecting blood pressure regulation, medication response, and long-term cardiovascular risk.

Genetic screening has evolved from simple risk assessment to comprehensive evaluation of multiple genetic variants affecting cardiovascular health. Modern screening protocols incorporate analysis of both common and rare variants, with particular attention to those with increased prevalence or unique significance in African populations. This sophisticated genetic analysis enables early identification of high-risk individuals and facilitates the implementation of preventive strategies before clinical manifestation of hypertension [101].

The application of advanced genomic technologies, including next-generation sequencing and sophisticated bioinformatic analyses, has revolutionized our understanding of genetic influences on blood pressure regulation. These technologies enable detailed assessment of genetic variants affecting multiple physiological pathways, including sodium handling, vascular reactivity, and sympathetic nervous system function [102].

6.1.2. Risk Stratification

The integration of genetic data with traditional clinical parameters has dramatically improved the accuracy of cardiovascular risk prediction models. This combined approach considers both inherited susceptibilities and acquired risk factors, enabling more precise risk assessment than conventional methods alone. Advanced statistical models incorporating genetic information have demonstrated superior predictive value for both disease onset and progression, particularly in African populations where traditional risk algorithms may be less accurate [103]. Individual genetic profiles serve as powerful tools for identifying patients who may benefit from more intensive monitoring or earlier therapeutic intervention. This approach enables the detection of high-risk genetic variants that might not be apparent through conventional clinical assessment. The ability to identify genetic predispositions to accelerated disease progression or increased complications allows for proactive implementation of preventive strategies and more aggressive risk factor modification [104].

The development of sophisticated risk stratification algorithms incorporating genetic information has transformed resource allocation in healthcare systems. These algorithms enable more efficient distribution of healthcare resources by identifying individuals most likely to benefit from intensive intervention or specialized care. This is particularly valuable in resource-limited settings, where optimal allocation of healthcare resources is crucial for maximizing population health outcomes [105].

6.2. Pharmacological Factors

6.2.1. Drug Selection

The impact of genetic variations on antihypertensive drug effectiveness has emerged as a crucial consideration in therapeutic decision-making. Different genetic profiles can significantly alter drug responsiveness, side effect susceptibility, and long-term outcomes. Understanding these genetic influences enables more precise selection of antihypertensive medications, potentially improving therapeutic efficacy while reducing adverse effects [106]. Pharmacogenetic testing has evolved into an essential tool for optimizing medication selection in hypertension management. This testing identifies genetic variants affecting drug metabolism, receptor function, and therapeutic response, enabling more informed drug selection. The integration of pharmacogenetic information into clinical practice supports evidence-based decision-making in choosing initial therapy and subsequent medication adjustments [107]. The unique genetic landscape of African populations necessitates careful consideration in antihypertensive drug selection. Certain genetic variants prevalent in African populations can significantly influence drug effectiveness and safety profiles. This population-specific genetic information guides the development of optimal drug combinations that account for both individual genetic profiles and population-level genetic patterns [108].

6.2.2. Dosing

Individual genetic profiles significantly influence drug metabolism and therapeutic response, necessitating personalized dosing strategies. Genetic variations can affect drug absorption, distribution, metabolism, and excretion, leading to substantial differences in drug effectiveness and safety among individuals [109]. Genetic variations in drug-metabolizing enzymes, particularly prevalent in African populations, require careful consideration in medication dosing. These genetic differences can lead to altered drug metabolism rates, affecting both drug efficacy and safety profiles. Recognition of these genetic variations enables proactive dose adjustments to optimize therapeutic outcomes while minimizing adverse effects [110]. The implementation of sophisticated drug monitoring protocols, incorporating both pharmacokinetic and pharmacodynamic parameters, has become essential for optimizing treatment regimens. Regular monitoring of drug levels and therapeutic response, guided by genetic information, enables dynamic dose adjustment and personalization of treatment strategies. This approach ensures optimal drug effectiveness while maintaining safety through careful consideration of individual genetic factors affecting drug handling and response [111]



Figure 2. Management of Hypertension in African Populations

Table 3. Treatment in African Populations

Aspect	Clinical Considerations	Challenges	Optimization
First-line Therapy	Population-specific response	Availability issues	Local guidelines adaptation
Combination Therapy	Synergistic effects	Cost considerations	Rational drug combinations
Traditional Medicine	Cultural integration	Standardization needs	Evidence-based integration
Adherence Support	Behavioral factors	Resource limitations	Community engagement
Monitoring	Regular assessment	Access barriers	Innovative solutions

Table 4. Treatment Response Patterns in African Populations

Drug Class	Response Rate (%)	Major Side Effects	Cost-Effectiveness	Recommendation Level
Thiazide diuretics	65-75	Metabolic effects	High	First-line
CCBs	60-70	Edema	Moderate	First-line
ACE inhibitors	45-55	Cough, angioedema	Moderate	Second-line
ARBs	50-60	Generally well-tolerated	Low	Second-line
Beta-blockers	40-50	Fatigue, bradycardia	Moderate	Third-line

6.3. Lifestyle Factors

6.3.1. Dietary Recommendations

The formulation of dietary recommendations for African populations requires a sophisticated understanding of the interplay between genetic predispositions, metabolic responses, and cultural dietary patterns [112]. Salt sensitivity testing has emerged as a crucial component in developing personalized sodium restriction guidelines, with particular attention to the high prevalence of salt-sensitive hypertension in African populations. This testing enables healthcare providers to establish evidence-based, individualized sodium intake targets that optimize blood pressure control while maintaining dietary palatability [113]. Nutritional counseling must transcend traditional one-size-fits-all approaches, incorporating deep understanding of cultural food preferences, socioeconomic constraints, and genetic factors that influence nutrient metabolism. This comprehensive approach includes consideration of traditional African dietary patterns, local food availability, and specific genetic polymorphisms affecting nutrient processing. The

combination of these factors affects the development of sustainable, culturally appropriate dietary modifications that enhance therapeutic outcomes while maintaining cultural food traditions [114].

6.3.2. Physical Activity Programs

Exercise prescriptions in African populations demand careful consideration of individual cardiovascular responses, which can vary significantly based on genetic predispositions and environmental factors [115]. Research has revealed substantial variability in exercise-induced cardiovascular adaptations among African populations, influenced by specific genetic variants affecting cardiovascular function and exercise metabolism [116].

The design of physical activity programs must balance optimal cardiovascular benefit with safety considerations, accounting for individual risk factors and genetic predispositions. This approach involves careful assessment of exercise intensity, duration, and modality, with regular monitoring of cardiovascular responses. Implementation of tailored activity programs includes consideration of environmental factors, such as climate and available facilities, while incorporating traditional physical activities that may have cultural significance [117].



Figure 3: Risk Factors and Prevention Strategies in African Hypertension

6.4. Monitoring and Follow-up

6.4.1. Blood Pressure

Contemporary blood pressure monitoring protocols must evolve beyond standard clinical measurements to incorporate comprehensive risk assessment based on individual genetic and environmental factors [118]. Home blood pressure monitoring programs, increasingly recognized as crucial for accurate diagnosis and management, now integrate consideration of genetic risk factors that influence blood pressure variability and circadian patterns. This integration enables more precise risk stratification and treatment optimization [119]. The implementation of advanced monitoring technologies, including ambulatory blood pressure monitoring and novel wearable devices, has revolutionized our ability to detect and characterize blood pressure patterns. These technologies provide information about nocturnal blood pressure patterns, morning surge, and blood pressure variability, all of which have particular relevance in African populations due to unique genetic and environmental influences [120].

6.4.2. Treatment Response

The assessment of treatment effectiveness requires systematic evaluation protocols that consider both immediate blood pressure response and long-term cardiovascular outcomes [121]. Regular monitoring of biomarkers, including markers of organ damage and vascular function, provides crucial information about disease progression and treatment efficacy. This monitoring strategy enables early detection of target organ damage and allows for timely therapeutic adjustments [122]. Long-term follow-up strategies must incorporate both genetic factors that influence disease progression and environmental factors that affect treatment adherence and outcomes. This approach includes regular assessment of medication adherence, monitoring of side effects, and evaluation of lifestyle modifications, all while considering the unique genetic and environmental context of African populations [123].



Figure 4: Target Organ Damage in African Hypertension

6.5. Public Health

6.5.1. Population Screening

The implementation of systematic screening programs requires careful consideration of population-specific risk factors and resource allocation [124]. The integration of genetic testing in population health programs, while presenting logistical and ethical challenges, offers opportunities for more precise risk stratification and early intervention. This approach must balance the potential benefits of genetic information with cost-effectiveness and healthcare system capabilities [125]. Community-based screening initiatives have demonstrated particular effectiveness in African populations, especially when integrated with existing healthcare infrastructure and community resources. These programs enhance early detection of hypertension while providing opportunities for health education and community engagement. Success requires careful consideration of local healthcare resources, cultural factors, and community needs [126].

Table 5. Healthcare System Components for Hypertension Management

Component	Urban Setting	Rural Setting	Development Needs
Primary Care	Variable access	Limited availability	Infrastructure development
Specialist Care	Limited availability	Rarely available	Capacity building
Diagnostic Services	Partial coverage	Minimal coverage	Equipment and training
Medication Supply	Irregular access	Poor access	Supply chain strengthening
Health Education	Multiple channels	Limited reach	Community-based programs

6.5.2. Health Education

Educational programs must address population-specific risk factors while considering local health beliefs and practices [127]. Cultural competency in health communication extends beyond simple translation of materials to include understanding of health beliefs, traditional practices, and social structures that influence health behaviors. This approach ensures that health messages

resonate with target populations and effectively promote behavior change [128]. Community engagement in health education requires sustained, culturally appropriate interventions that build trust and promote long-term behavioral change. Successful programs incorporate community leaders, traditional healers, and local health advocates in program design and implementation. This collaborative approach ensures that interventions are both culturally appropriate and sustainable, leading to improved health outcomes through enhanced community participation and ownership [129].

7. Conclusion

The pathophysiology of hypertension in African populations shows a strong correlation between genetic predisposition and environmental influences. The higher prevalence and severity of hypertension in these populations stem from unique genetic variations affecting blood pressure regulation, particularly in the RAAS pathway, endothelial function, and sodium handling mechanisms. These genetic factors interact with modern lifestyle changes, including altered dietary patterns, reduced physical activity, and increased psychosocial stress, creating a perfect storm for hypertension development. Recent advances in genetic research and personalized medicine offer promising approaches for improving hypertension management in African populations. Integration of genetic screening, pharmacogenetic testing, and targeted therapeutic strategies enables more precise and effective treatment. However, successful implementation requires addressing socioeconomic barriers and ensuring healthcare accessibility.

References

[1] Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Dennison Himmelfarb C, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults. J Am Coll Cardiol. 2018;71(19):e127-e248.

[2] Brewster LM, Seedat YK. Why do hypertensive patients of African ancestry respond better to calcium blockers and diuretics than to ACE inhibitors and β-adrenergic blockers? A systematic review. BMC Med. 2013;11:141.

[3] Zilbermint M, Gaye A, Berthon A, Hannah-Shmouni F, Faucz FR, Davis AR, et al. ARMC5 variants and risk of hypertension in blacks: MH-GRID study. J Am Heart Assoc. 2019;8(24):e012508.

[4] Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018;39(33):3021-3104.

[5] Peprah E, Xu H, Tekola-Ayele F, Royal CD. Genome-wide association studies in Africans and African Americans: expanding the framework of personalized medicine in diverse populations. Public Health Genomics. 2015;18(6):349-66.

[6] Ataklte F, Erqou S, Kaptoge S, Taye B, Echouffo-Tcheugui JB, Kengne AP. Burden of undiagnosed hypertension in sub-Saharan Africa: a systematic review and meta-analysis. Hypertension. 2015;65(2):291-8.

[7] Addo J, Smeeth L, Leon DA. Hypertension in sub-Saharan Africa: a systematic review. Hypertension. 2007;50(6):1012-8.

[8] Cooper RS, Forrester TE, Plange-Rhule J, Bovet P, Lambert EV, Dugas LR, et al. Elevated hypertension risk for African-origin populations in biracial societies: modeling the Epidemiologic Transition Study. J Hypertens. 2015;33(3):473-80.

[9] Akinyemi RO, Ovbiagele B, Adeniji OA, Sarfo FS, Abd-Allah F, Adoukonou T, et al. Stroke in Africa: profile, progress, prospects and priorities. Nat Rev Neurol. 2021;17(10):634-656.

[10] Spence JD, Rayner BL. Hypertension in Blacks: individualized therapy based on renin/aldosterone phenotyping. Hypertension. 2018;72(2):263-269.

[11] Cappuccio FP, Miller MA. Cardiovascular disease and hypertension in sub-Saharan Africa: burden, risk and interventions. Intern Emerg Med. 2016;11(3):299-305.

[12] Rotimi CN, Bentley AR, Doumatey AP, Chen G, Shriner D, Adeyemo A. The genomic landscape of African populations in health and disease. Hum Mol Genet. 2017;26(R2):R225-R236.

[13] Seedat YK. Why is control of hypertension in sub-Saharan Africa poor? Cardiovasc J Afr. 2015;26(4):193-5.

[14] Opie LH, Seedat YK. Hypertension in sub-Saharan African populations. Circulation. 2005;112(23):3562-8.

[15] Ojji DB, Mayosi B, Francis V, Badri M, Cornelius V, Smythe W, et al. Comparison of dual therapies for lowering blood pressure in black Africans. N Engl J Med. 2019;380(25):2429-2439

[16] Dzudie A, Rayner B, Ojji D, Schutte AE, Twagirumukiza M, Damasceno A, et al. Roadmap to achieve 25% hypertension control in Africa by 2025. Glob Heart. 2018;13(1):45-59.

[17] Akhabue E, Thiboutot J, Cheng JW, Vittorio TJ, Christodoulidis G, Grady KM, et al. New and emerging risk factors for heart failure. Am J Med Sci. 2017;354(2):105-112.

[18] Gafane LF, Schutte R, Van Rooyen JM, Schutte AE. Plasma renin and cardiovascular responses to the cold pressor test differ in black and white populations. J Hum Hypertens. 2016;30(5):346-51.

[19] Kopp JB. Genetic clues to understanding treatment responses in African Americans. Nat Rev Nephrol. 2020;16(4):187-188.

[20] Mensah GA, Mokdad AH, Ford ES, Greenlund KJ, Croft JB. State of disparities in cardiovascular health in the United States. Circulation. 2005;111(10):1233-41.

[21] Price DA, Fisher ND. The renin-angiotensin system in blacks: active, passive, or what? Curr Hypertens Rep. 2003;5(3):225-30.

[22] Reiter CD, Wang X, Tanus-Santos JE, Hogg N, Cannon RO 3rd, Schechter AN, et al. Cell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease. Nat Med. 2002;8(12):1383-9.

[23] Sagnella GA. Why is plasma renin activity lower in populations of African origin? J Hum Hypertens. 2001;15(1):17-25.

[24] Tayo BO, Luke A, Zhu X, Adeyemo A, Cooper RS. Association of regions on chromosomes 6 and 7 with blood pressure in Nigerian families. Circ Cardiovasc Genet. 2009;2(1):38-45.

[25] Wright JT Jr, Dunn JK, Cutler JA, Davis BR, Cushman WC, Ford CE, et al. Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinopril. JAMA. 2005;293(13):1595-608.

[26] Young JH, Chang YP, Kim JD, Chretien JP, Klag MJ, Levine MA, et al. Differential susceptibility to hypertension is due to selection during the out-of-Africa expansion. PLoS Genet. 2005;1(6):e82.

[27] Zilbermint M, Hannah-Shmouni F, Stratakis CA. Genetics of hypertension in African Americans and others of African descent. Int J Mol Sci. 2019;20(5):1081.

[28] Zhao Q, Kelly TN, Li C, He J. Progress and future aspects in genetics of human hypertension. Curr Hypertens Rep. 2013;15(6):676-86.

[29] Ferdinand KC, Yadav K, Nasser SA, Clayton-Jeter HD, Lewin J, Cryer DR, et al. Disparities in hypertension and cardiovascular disease in blacks: the critical role of medication adherence. J Clin Hypertens (Greenwich). 2017;19(10):1015-1024.

[30] Forrester T. Historic and early life origins of hypertension in Africans. J Nutr. 2004;134(1):211-6.

[31] Grim CE, Robinson M. Salt, slavery and survival: physiological principles underlying the evolutionary hypothesis of salt-sensitive hypertension in western hemisphere blacks. Clin Exp Pharmacol Physiol. 2016;43(12):1183-1196.

[32] Arnett DK, Baird AE, Barkley RA, Basson CT, Boerwinkle E, Ganesh SK, et al. Relevance of genetics and genomics for prevention and treatment of cardiovascular disease. Circulation. 2007;115(22):2878-901.

[33] Bidulescu A, Ferguson TS, Hambleton I, Younger-Coleman N, Francis D, Bennett N, et al. Educational health disparities in hypertension and diabetes mellitus among African descent populations in the Caribbean and the USA. J Epidemiol Community Health. 2017;71(2):166-173.

[34] Bochud M, Bovet P, Elston RC, Paccaud F, Falconnet C, Maillard M, et al. High heritability of ambulatory blood pressure in families of East African descent. Hypertension. 2005;45(3):445-50.

[35] Cooper RS, Wolf-Maier K, Luke A, Adeyemo A, Banegas JR, Forrester T, et al. An international comparative study of blood pressure in populations of European vs. African descent. BMC Med. 2005;3:2.

[36] Daniel HI, Rotimi CN. Genetic epidemiology of hypertension: an update on the African diaspora. Ethn Dis. 2003;13(2 Suppl 2):S53-66.

[37] Flack JM, Sica DA, Bakris G, Brown AL, Ferdinand KC, Grimm RH Jr, et al. Management of high blood pressure in Blacks: an update of the International Society on Hypertension in Blacks consensus statement. Hypertension. 2010;56(5):780-800.

[38] Gafane-Matemane LF, Hoebel S, Burger A, Mels CMC, Schutte AE. Plasma renin and aldosterone responses to low-sodium diet and acute salt loading in young healthy adults of African descent. J Hum Hypertens. 2020;34(5):371-377.

[39] Gavin JR 3rd, Wright EE Jr, Oh BK, Pettus JH. COVID-19 & diabetes: implications for people of African descent. Ethn Dis. 2020;30(3):401-408.

[40] Gu D, Chen J, Wu X, Duan X, Jones DW, Huang JF, et al. Effect of blood pressure and blood pressure change on mortality in the Chinese population. J Hypertens. 2019;37(8):1541-1550.

[41] Kagura J, Adair LS, Munthali RJ, Pettifor JM, Norris SA. Association between early life growth and blood pressure trajectories in black South African children. Hypertension. 2016;68(5):1123-1131.

[42] Lemogoum D, Seedat YK, Mabadeje AF, Mendis S, Bovet P, Onwubere B, et al. Recommendations for prevention, diagnosis and management of hypertension and cardiovascular risk factors in sub-Saharan Africa. J Hypertens. 2003;21(11):1993-2000.

[43] Luft FC. Molecular genetics of human hypertension. J Hypertens. 1998;16(12 Pt 2):1871-8.

[44] Mayosi BM, Fish M, Shaboodien G, Mastantuono E, Kraus S, Wieland T, et al. Identification of Cadherin 2 (CDH2) mutations in arrhythmogenic right ventricular cardiomyopathy. Circ Cardiovasc Genet. 2017;10(2):e001605.

[45] Mensah GA, Jaquish C, Thorpe P, Douglas J, Tobin JN, Kingston RS, et al. Reducing cardiovascular disease and end-stage renal disease in a minority community: Project EXPORT. Ethn Dis. 2004;14(3 Suppl 1):S2-71-80.

[46] Ogedegbe G, Shah NR, Phillips C, Goldfeld K, Roy J, Guo Y, et al. Comparative effectiveness of angiotensin-converting enzyme inhibitor-based treatment on cardiovascular outcomes in hypertensive blacks versus whites. J Am Coll Cardiol. 2015;66(11):1224-1233.

[47] Opie LH, Mayosi BM. Cardiovascular disease in sub-Saharan Africa. Circulation. 2005;112(23):3536-40.

[48] Raji YR, Mabayoje M, Bello AK. Epidemiology and etiology of hypertension in Africa: a systematic review and meta-analysis. J Clin Hypertens (Greenwich). 2021;23(6):1117-1128.

[49] Rotimi C, Cooper R, Cao G, Sundarum C, McGee D. Familial aggregation of cardiovascular diseases in African-American pedigrees. Genet Epidemiol. 1994;11(5):397-407.

[50] Sankoh O, Byass P. The INDEPTH Network: filling vital gaps in global epidemiology. Int J Epidemiol. 2012;41(3):579-88.

[51] Schutte AE, Botha S, Fourie CMT, Gafane-Matemane LF, Kruger R, Lammertyn L, et al. Recent advances in understanding hypertension development in sub-Saharan Africa. J Hum Hypertens. 2017;31(8):491-500.

[52] Seedat YK, Rayner BL, Veriava Y. South African hypertension practice guideline 2014. Cardiovasc J Afr. 2014;25(6):288-94.

[53] Tekola-Ayele F, Doumatey AP, Shriner D, Bentley AR, Chen G, Zhou J, et al. Genome-wide association study identifies African-ancestry specific variants for metabolic syndrome. Mol Genet Metab. 2015;116(4):305-13.

[54] Tiffin N, Meintjes A, Ramesar R, Bajic VB, Rayner B. Computational analysis of candidate disease genes and variants for salt-sensitive hypertension in indigenous Southern Africans. PLoS One. 2010;5(9):e12989.

[55] Twagirumukiza M, De Bacquer D, Kips JG, de Backer G, Stichele RV, Van Bortel LM. Current and projected prevalence of arterial hypertension in sub-Saharan Africa by sex, age and habitat: an estimate from population studies. J Hypertens. 2011;29(7):1243-52.

[56] van de Vijver S, Akinyi H, Oti S, Olajide A, Agyemang C, Aboderin I, et al. Status report on hypertension in Africa - consultative review for the 6th Session of the African Union Conference of Ministers of Health on NCD's. Pan Afr Med J. 2013;16:38.

[57] Weber MA, Schiffrin EL, White WB, Mann S, Lindholm LH, Kenerson JG, et al. Clinical practice guidelines for the management of hypertension in the community: a statement by the American Society of Hypertension and the International Society of Hypertension. J Clin Hypertens (Greenwich). 2014;16(1):14-26.

[58] Weinberg CR, Morris RW. Invited commentary: Testing for Hardy-Weinberg disequilibrium using a genome single-nucleotide polymorphism scan based on cases only. Am J Epidemiol. 2003;158(5):401-3.

[59] Yancy CW. COVID-19 and African Americans. JAMA. 2020;323(19):1891-1892.

[60] Zhu X, Luke A, Cooper RS, Quertermous T, Hanis C, Mosley T, et al. Admixture mapping for hypertension loci with genome-scan markers. Nat Genet. 2005;37(2):177-81.

[61] Zhou MS, Schulman IH, Raij L. Vascular inflammation, insulin resistance, and endothelial dysfunction in salt-sensitive hypertension: role of nuclear factor kappa B activation. J Hypertens. 2010;28(3):527-35.

[62] Agyemang C, Nyaaba G, Beune E, Meeks K, Owusu-Dabo E, Addo J, et al. Variations in hypertension awareness, treatment, and control among Ghanaian migrants living in Amsterdam, Berlin, London, and nonmigrant Ghanaians living in rural and urban Ghana - the RODAM study. J Hypertens. 2018;36(1):169-177.

[63] Ojji DB, Poulter NR, Damasceno A, Sliwa K. A review of the evolution of hypertension guidelines in Africa. J Clin Hypertens (Greenwich). 2020;22(7):1224-1236.

[64] Mokdad AH, Ford ES, Bowman BA, Dietz WH, Vinicor F, Bales VS, et al. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA. 2003;289(1):76-9.

[65] Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. Lancet. 2005;365(9455):217-23.

[66] Gaziano TA, Abrahams-Gessel S, Denman CA, Montano CM, Khanam M, Puoane T, et al. An assessment of community health workers' ability to screen for cardiovascular disease risk with a simple, non-invasive risk assessment instrument in Bangladesh, Guatemala, Mexico, and South Africa: an observational study. Lancet Glob Health. 2015;3(9):e556-63.

[67] Sliwa K, Ojji D, Damasceno A, Davison BA, Mayosi BM, Damasceno A, et al. Factors associated with interhospital transfer of patients with acute heart failure: a substudy of the THESUS-HF registry. ESC Heart Fail. 2015;2(4):150-158.

[68] Cooper RS, Kaufman JS, Ward R. Race and genomics. N Engl J Med. 2003;348(12):1166-70.

[69] Bärnighausen T, Welz T, Hosegood V, Bätzing-Feigenbaum J, Tanser F, Herbst K, et al. Hiding in the shadows of the HIV epidemic: obesity and hypertension in a rural population with very high HIV prevalence in South Africa. J Hum Hypertens. 2008;22(3):236-9.

[70] Delles C, McBride MW, Graham D, Padmanabhan S, Dominiczak AF. Genetics of hypertension: from experimental animals to humans. Biochim Biophys Acta. 2010;1802(12):1299-308.

[71] Lopes AA, Hornbuckle K, James SA, Port FK. The joint effects of race and age on the risk of end-stage renal disease attributed to hypertension. Am J Kidney Dis. 1994;24(4):554-60.

[72] Ataklte F, Erqou S, Kaptoge S, Taye B, Echouffo-Tcheugui JB, Kengne AP. Burden of undiagnosed hypertension in sub-Saharan Africa: a systematic review and meta-analysis. Hypertension. 2015;65(2):291-8.

[73] Opie LH. Heart disease in Africa. Lancet. 2006;368(9534):449-50.

[74] Damasceno A, Mayosi BM, Sani M, Ogah OS, Mondo C, Ojji D, et al. The causes, treatment, and outcome of acute heart failure in 1006 Africans from 9 countries. Arch Intern Med. 2012;172(18):1386-94.

[75] Brewster LM, van Montfrans GA, Kleijnen J. Systematic review: antihypertensive drug therapy in black patients. Ann Intern Med. 2004;141(8):614-27.

[76] Inamo J, Lang T, Atallah A, Inamo A, Larabi L, Chatellier G, et al. Prevalence and therapeutic control of hypertension in French Caribbean regions. J Hypertens. 2005;23(7):1341-6.

[77] Gu D, Reynolds K, Wu X, Chen J, Duan X, Muntner P, et al. Prevalence, awareness, treatment, and control of hypertension in China. Hypertension. 2002;40(6):920-7.

[78] Ferdinand KC, Ferdinand DP. Race-based therapy for hypertension: possible benefits and potential pitfalls. Expert Rev Cardiovasc Ther. 2008;6(10):1357-66.

[79] Opie LH, Seedat YK. Hypertension in sub-Saharan African populations. Circulation. 2005;112(23):3562-8.

[80] Okin PM, Kjeldsen SE, Dahlöf B, Devereux RB. Racial differences in incident heart failure during antihypertensive therapy. Circ Cardiovasc Qual Outcomes. 2011;4(2):157-64.

[81] Signorello LB, Schlundt DG, Cohen SS, Steinwandel MD, Buchowski MS, McLaughlin JK, et al. Comparing diabetes prevalence between African Americans and Whites of similar socioeconomic status. Am J Public Health. 2007;97(12):2260-7.

[82] Kramer H, Han C, Post W, Goff D, Diez-Roux A, Cooper R, et al. Racial/ethnic differences in hypertension and hypertension treatment and control in the multi-ethnic study of atherosclerosis (MESA). Am J Hypertens. 2004;17(10):963-70.

[83] Oparil S, Wright JT Jr. Ethnicity and blood pressure. J Clin Hypertens (Greenwich). 2005;7(6):357-64.

[84] Redmond N, Baer HJ, Hicks LS. Health behaviors and racial disparity in blood pressure control in the national health and nutrition examination survey. Hypertension. 2011;57(3):383-9.

[85] Sacks FM, Svetkey LP, Vollmer WM, Appel LJ, Bray GA, Harsha D, et al. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. N Engl J Med. 2001;344(1):3-10.

[86] Taylor JY, Sun YV, Hunt SC, Kardia SL. Gene-environment interaction for hypertension among African American women across generations. Biol Res Nurs. 2010;12(2):149-55.

[87] Tayo BO, Luke A, McKenzie CA, Kramer H, Cao G, Durazo-Arvizu R, et al. Patterns of sodium and potassium excretion and blood pressure in the African Diaspora. J Hum Hypertens. 2012;26(5):315-24.

[88] Victor RG, Ravenell JE, Freeman A, Leonard D, Bhat DG, Shafiq M, et al. Effectiveness of a barber-based intervention for improving hypertension control in black men: the BARBER-1 study: a cluster randomized trial. Arch Intern Med. 2011;171(4):342-50.

[89] Wright JT Jr, Bakris G, Greene T, Agodoa LY, Appel LJ, Charleston J, et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA. 2002;288(19):2421-31.

[90] Zhu X, Young JH, Fox E, Keating BJ, Franceschini N, Kang S, et al. Combined admixture mapping and association analysis identifies a novel blood pressure genetic locus on 5p13: contributions from the CARe consortium. Hum Mol Genet. 2011;20(11):2285-95.

[91] Ibrahim MM, Damasceno A. Hypertension in developing countries. Lancet. 2012;380(9841):611-9.

[92] Mocumbi AO. Lack of focus on cardiovascular disease in sub-Saharan Africa. Cardiovasc Diagn Ther. 2012;2(1):74-7.

[93] Ataklte F, Erqou S, Kaptoge S, Taye B, Echouffo-Tcheugui JB, Kengne AP. Burden of undiagnosed hypertension in sub-Saharan Africa: a systematic review and meta-analysis. Hypertension. 2015;65(2):291-8.

[94] Turnbull F, Neal B, Algert C, Chalmers J, Chapman N, Cutler J, et al. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials. Arch Intern Med. 2005;165(12):1410-9.

[95] Bhatt DL, Kandzari DE, O'Neill WW, D'Agostino R, Flack JM, Katzen BT, et al. A controlled trial of renal denervation for resistant hypertension. N Engl J Med. 2014;370(15):1393-401.

[96] Cooper RS, Rotimi CN, Ward R. The puzzle of hypertension in African-Americans. Sci Am. 1999;280(2):56-63.

[97] Cruickshank JK, Mbanya JC, Wilks R, Balkau B, McFarlane-Anderson N, Forrester T. Sick genes, sick individuals or sick populations with chronic disease? The emergence of diabetes and high blood pressure in African-origin populations. Int J Epidemiol. 2001;30(1):111-7.

[98] Kaufman JS, Cooper RS, McGee DL. Socioeconomic status and health in blacks and whites: the problem of residual confounding and the resiliency of race. Epidemiology. 1997;8(6):621-8.

[99] Lewington S, Clarke R, Qizilbash N, Peto R, Collins R; Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360(9349):1903-13.

[100] Lloyd-Jones DM, Hong Y, Labarthe D, Mozaffarian D, Appel LJ, Van Horn L, et al. Defining and setting national goals for cardiovascular health promotion and disease reduction: the American Heart Association's strategic Impact Goal through 2020 and beyond. Circulation. 2010;121(4):586-613.

[101] Mensah GA, Roth GA, Sampson UK, Moran AE, Feigin VL, Forouzanfar MH, et al. Mortality from cardiovascular diseases in sub-Saharan Africa, 1990-2013: a systematic analysis of data from the Global Burden of Disease Study 2013. Cardiovasc J Afr. 2015;26(2 Suppl 1):S6-10.

[102] O'Donnell MJ, Xavier D, Liu L, Zhang H, Chin SL, Rao-Melacini P, et al. Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study. Lancet. 2010;376(9735):112-23.

[103] Opie LH, Lecour S. The red wine hypothesis: from concepts to protective signalling molecules. Eur Heart J. 2007;28(14):1683-93.

[104] Peprah E, Xu H, Tekola-Ayele F, Royal CD. Genome-wide association studies in Africans and African Americans: expanding the framework of personalized medicine in diverse populations. Public Health Genomics. 2015;18(6):349-66.

[105] Sliwa K, Wilkinson D, Hansen C, Ntyintyane L, Tibazarwa K, Becker A, et al. Spectrum of heart disease and risk factors in a black urban population in South Africa (the Heart of Soweto Study): a cohort study. Lancet. 2008;371(9616):915-22.

[106] Steyn K, Sliwa K, Hawken S, Commerford P, Onen C, Damasceno A, et al. Risk factors associated with myocardial infarction in Africa: the INTERHEART Africa study. Circulation. 2005;112(23):3554-61.

[107] van der Sande MA, Milligan PJ, Nyan OA, Rowley JT, Banya WA, Ceesay SM, et al. Blood pressure patterns and cardiovascular risk factors in rural and urban gambian communities. J Hum Hypertens. 2000;14(8):489-96.

[108] Mayosi BM, Flisher AJ, Lalloo UG, Sitas F, Tollman SM, Bradshaw D. The burden of non-communicable diseases in South Africa. Lancet. 2009;374(9693):934-47.

[109] Raal FJ, Santos RD, Blom DJ, Marais AD, Charng MJ, Cromwell WC, et al. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. Lancet. 2010;375(9719):998-1006.

[110] Sliwa K, Mayosi BM. Recent advances in the epidemiology, pathogenesis and prognosis of acute heart failure and cardiomyopathy in Africa. Heart. 2013;99(18):1317-22.

[111] Tibazarwa K, Ntyintyane L, Sliwa K, Gerntholtz T, Carrington M, Wilkinson D, et al. A time bomb of cardiovascular risk factors in South Africa: results from the Heart of Soweto Study "Heart Awareness Days". Int J Cardiol. 2009;132(2):233-9.

[112] Amoah AG, Kallen C. Aetiology of heart failure as seen from a National Cardiac Referral Centre in Africa. Cardiology. 2000;93(1-2):11-8.

[113] Cruickshank JK, Mzayek F, Liu L, Kieltyka L, Sherwin R, Webber LS, et al. Origins of the "black/white" difference in blood pressure: roles of birth weight, postnatal growth, early blood pressure, and adolescent body size: the Bogalusa heart study. Circulation. 2005;111(15):1932-7.

[114] Damasceno A, Cotter G, Dzudie A, Sliwa K, Mayosi BM. Heart failure in sub-Saharan Africa: time for action. J Am Coll Cardiol. 2007;50(17):1688-93.

[115] Gona P, Van Dyke RB, Williams PL, Dankner WM, Chernoff MC, Nachman SA, et al. Incidence of opportunistic and other infections in HIV-infected children in the HAART era. JAMA. 2006;296(3):292-300.

[116] Hendriks ME, Wit FW, Roos MT, Brewster LM, Akande TM, de Beer IH, et al. Hypertension in sub-Saharan Africa: cross-sectional surveys in four rural and urban communities. PLoS One. 2012;7(3):e32638.

[117] Kaufman JS, Owoaje EE, James SA, Rotimi CN, Cooper RS. Determinants of hypertension in West Africa: contribution of anthropometric and dietary factors to urban-rural and socioeconomic gradients. Am J Epidemiol. 1996;143(12):1203-18.

[118] Mayosi BM, Lawn JE, van Niekerk A, Bradshaw D, Abdool Karim SS, Coovadia HM; Lancet South Africa team. Health in South Africa: changes and challenges since 2009. Lancet. 2012;380(9858):2029-43.

[119] Mensah GA. Epidemiology of stroke and high blood pressure in Africa. Heart. 2008;94(6):697-705.

[120] Rayner B. Hypertension: detection and management in South Africa. Nephron Clin Pract. 2010;116(4):c269-73.

[121] Seedat YK, Rayner BL. The text book of hypertension and cardiovascular disease in Africa. Durban: Churchill Livingstone; 2016.

[122] Steyn K, Gaziano TA, Bradshaw D, Laubscher R, Fourie J; South African Demographic and Health Coordinating Team. Hypertension in South African adults: results from the Demographic and Health Survey, 1998. J Hypertens. 2001;19(10):1717-25.

[123] Tibazarwa KB, Volmink JA, Mayosi BM. Incidence of acute rheumatic fever in the world: a systematic review of population-based studies. Heart. 2008;94(12):1534-40.

[124] van Rooyen JM, Kruger HS, Huisman HW, Wissing MP, Margetts BM, Venter CS, et al. An epidemiological study of hypertension and its determinants in a population in transition: the THUSA study. J Hum Hypertens. 2000;14(12):779-87.

[125] Vorster HH, Kruger A, Venter CS, Margetts BM, Macintyre UE. Cardiovascular disease risk factors and socio-economic position of Africans in transition: the THUSA study. Cardiovasc J Afr. 2007;18(5):282-9.

[126] Walker AR, Walker BF, Segal I. Some puzzling situations in the onset, occurrence and future of coronary heart disease in developed and developing populations, particularly such in sub-Saharan Africa. J R Soc Promot Health. 2004;124(1):40-6.

[127] Watkins D, Zuhlke L, Engel M, Daniels R, Francis V, Shaboodien G, et al. Seven key actions to eradicate rheumatic heart disease in Africa: the Addis Ababa communiqué. Cardiovasc J Afr. 2016;27(3):184-7.

[128] Yusuf S, Reddy S, Ounpuu S, Anand S. Global burden of cardiovascular diseases: part I: general considerations, the epidemiologic transition, risk factors, and impact of urbanization. Circulation. 2001;104(22):2746-53.

[129] Zühlke L, Engel ME, Karthikeyan G, Rangarajan S, Mackie P, Cupido B, et al. Characteristics, complications, and gaps in evidence-based interventions in rheumatic heart disease: the Global Rheumatic Heart Disease Registry (the REMEDY study). Eur Heart J. 2015;36(18):1115-22a.